Ischemic stroke: A cardiovascular risk equivalent? Lessons learned from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial

Canadian Journal of Cardiology

Volumn 24, Issue 9, 2008, Pages 705-708

  Fitchett, David H ^a   Goodman, Shaun G ^a   Langer, Anatoly ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Atorvastatin; Cholesterol; Coronary artery disease; Stroke

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ARTICLE; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG MECHANISM; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; INCIDENCE; PRACTICE GUIDELINE; PROGNOSIS; RISK ASSESSMENT; RISK REDUCTION; TRANSIENT ISCHEMIC ATTACK; BLOOD; CHEMICALLY INDUCED DISORDER; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; STROKE;

CARDIOVASCULAR DISEASES; CEREBRAL HEMORRHAGE; CHOLESTEROL; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISCHEMIC ATTACK, TRANSIENT; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; STROKE;

EID: 54049115977     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(08)70669-X     Document Type: Article

References (21)

1. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet 1995;346:1647-53.
2. Bots ML, Elwood PC, Nikitin Y, et al. Total and HDL cholesterol and risk of stroke. EUROSTROKE: A collaborative study among research centres in Europe. J Epidemiol Community Health 2002;56(Suppl 1)i19-24.
3. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989;320:904-10.
4. Tirschwell DL, Smith NL, Heckbert SR, Lemaitre RN, Longstreth WT Jr, Psaty BM. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 2004;63:1868-75.
5. Walldius G, Aastveit AH, Jungner I. Stroke mortality and the apoB/apoA-I ratio: Results of the AMORIS prospective study. J Intern Med 2006;259:259-66.
6. Amarenco P, Labreuche J, Lavallefacute;e P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: Systematic review and up-to-date meta-analysis. Stroke 2004;35:2902-9.
7. Cannon CF, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006;48:438-45.
8. Sever PS, Poulter NR, Dahlöf B, Wedel H; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT,LLA). Am J Cardiol 2005;96:39F-44F.
9. Amarenco P, Bogousslavsky J, Callahan A III, et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischernic attack. N Engl J Med 2006;355:549-59.
10. Yano K, Reed DM, MacLean CJ. Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke 1989;20:1460-5.
11. Waters DD, Schwartz GG, Olsson AG, et al; MIRACL Study Investigators. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: A Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 2002;106:1690-5.
12. Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E; PROVE IT-TIMI 22 Investigators. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: A PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005;46:1411-6 (Erratum in 2006;47:472).
13. Waters DD, LaRosa JC, Barter P, et al. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (Treating to New Targets) study. J Am Coll Cardiol 2006;48:1793-9.
14. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-67.
15. Amarenco P, Goldstein LB, Szarek M, et al; SPARCL Investigators. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2007;38:3198-204.
16. Touzé E, Varenne O, Chatellier G, Peyrard S, Rodiwell PM, Mas JL. Risk of myocardial infarction and vascular death after transient ischemic attack and ischemic stroke: A systematic review and meta-analysis. Stroke 2005;36:2748-55.
17. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998;19:1434-503.
18. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999;100:1481-92.
19. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
20. McPherson R, Frohlich J, Fodor G, Genest J, Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement - recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22:913-27. (Erratum in 2006;22:1077).
21. Adams RJ, Chimowitz MI, Alpert JS, et al; Stroke Council and the Council on Clinical Cardiology of the American Heart Association; American Stroke Association. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: A scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Circulation 2003;108:1278-90.